Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   41232   clinical trials with a EudraCT protocol, of which   6757   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2011-004770-28
    Sponsor's Protocol Code Number:ST261-DM-11-006
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2012-01-11
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2011-004770-28
    A.3Full title of the trial
    Phase III, Parallel-group, Placebo Controlled, Double-blind, Randomized, Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-Carnitine (ST261) Modified Release Tablets in Patients Affected by Mild Ulcerative Colitis under Oral Stable Treatment.
    Estudio de Fase III, de grupos paralelos, controlado con placebo, doble ciego, aleatorizado, multicéntrico, internacional, para investigar la seguridad y eficacia de los comprimidos de liberación modificada de propionil-L-carnitina clorhidrato (ST 261) en pacientes afectados por colitis ulcerosa leve bajo tratamiento oral estable
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Investigation of the potential side effects and effects on the large bowel of Propionyl-L-carnitine Hydrochloride (ST 261) (given as tablets that release the active ingredient only in the large bowel) in Patients with Mild Ulcerative Colitis that are concomitantly treated with a Stable dose of aminosalicylates
    Investigación de los efectos secundarios potenciales y los efectos en el intestino grueso de la propionil-L-carnitina clorhidrato (ST 261) (como comprimidos que liberan el principio activo sólo en el intestino grueso) en pacientes con colitis ulcerosa leve que son tratados de forma concomitante con una dosis estable de aminosalicilatos
    A.3.2Name or abbreviated title of the trial where available
    Propionyl-L-Carnitine in Ulcerative Colitis
    Propionil-L-Carnitina en Colitis Ulcerosa
    A.4.1Sponsor's protocol code numberST261-DM-11-006
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorSigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    B.1.3.4CountryItaly
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportSigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    B.4.2CountryItaly
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationSigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    B.5.2Functional name of contact pointCarla Cucco
    B.5.3 Address:
    B.5.3.1Street AddressViale Shakespeare, 47
    B.5.3.2Town/ cityRome
    B.5.3.3Post code00144
    B.5.3.4CountryItaly
    B.5.4Telephone number+39-06-91394322
    B.5.5Fax number+39-06-91166976
    B.5.6E-mailcarla.cucco@sigma-tau.it
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePROPIONYL L-CARNITINE
    D.3.2Product code ST 261
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLevocarnitine propyl hydrochloride
    D.3.9.1CAS number 119793-66-7
    D.3.9.2Current sponsor code(ST261) Propionyl-L-carnitine hydrochloride
    D.3.9.3Other descriptive name(R)-3-(1-oxo-propoxy)-4-(N,N,N-trimethyl amonium chloride)-butanoic acid
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typenot less then
    D.3.10.3Concentration number500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Mild ulcerative colitis
    Colitis ulcerosa leve
    E.1.1.1Medical condition in easily understood language
    Mild non-infectious inflammation of the large bowel
    Inflamación no infecciosa leve del intestino grueso
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level LLT
    E.1.2Classification code 10066678
    E.1.2Term Acute ulcerative colitis
    E.1.2System Organ Class 10017947 - Gastrointestinal disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Compare the two treatment groups (ST 261 modified release
    tablets 1g/die vs. placebo) with respect to the proportion of patients with disease remission at the end of the 8 weeks of treatment
    Evaluation of safety and tolerability of ST 261
    Comparar los dos grupos de tratamiento (comprimidos de liberación modificada de ST 261 1 g/día frente a placebo) con respecto a la proporción de pacientes con remisión de la enfermedad al final de las 8 semanas de tratamiento.
    La evaluación de la seguridad y tolerabilidad de ST 261 también es un objetivo principal del estudio.
    E.2.2Secondary objectives of the trial
    Maintenance of remission after four weeks of treatment interruption, the histological changes, the disease symptoms (sub-scores) improvement and the overall quality of life as measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ).
    Mantenimiento de la remisión después de cuatro semanas de interrupción del tratamiento, los cambios histológicos, la mejoría en los síntomas de la enfermedad (puntuaciones) y la calidad de vida general medida por el Breve cuestionario de la Enfermedad Inflamatoria Intestinal (SIBDQ).
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Have read the Information for the Patient and signed the Informed Consent Form.
    2. Age comprised between 18 and 75 included.
    3. Diagnosis of active ulcerative colitis since at least 4 weeks as confirmed endoscopically (pancolonoscopy) and histologically. A new pancolonoscopy is required if documented evidence of having performed it within the previous 12 months is not available. If available, only a new colonoscopy for the visualization of the affected part of the colon is required for the evaluation of the baseline DAI score.
    4. Disease Activity Index comprised between 3 and 6, inclusive (mild ulcerative colitis), with rectal bleeding sub-score of at least 1.
    5. Stable background oral aminosalycilates (mesalazine, balsalazide, olsalazine) or sulfasalazine standard therapy for greater than or equal to 4 weeks prior to screening assessments.
    6. If female, not pregnant or nursing.
    7. For women of childbearing potential (WOCBP), willingness to avoid a pregnancy during the treatment period and for at least 4 weeks from the last dose of drug. A WOCBP is defined as any female who has experienced menarche and who has not ndergone
    successful surgical sterilisation (hysterectomy, bilateral tubal ligation or bilateral ovariectomy) or is not postmenopausal (defined as amenorrhoea >12 consecutive months). WOCBP should use an efficient method of birth control for the entire duration of the trial and until the first menses after a 30-day period after the last dose of trial medication. They must be
    on a stable regimen, for at least 1 month, of oral contraceptives, contraceptive implant or depot injection, contraceptive patch, intrauterine device (IUD), condom and spermicidal agent, or
    diaphragm and spermicidal agent. The patient will be informed about the
    result of the pregnancy test and of the allowed method of contraception
    and its duration
    1. Hayan leído la Información para el paciente y hayan firmado el Formulario de consentimiento informado.
    2. Tengan una edad comprendida entre los 18 y los 75 años, ambos inclusive.
    3. Tengan diagnóstico de colitis ulcerosa activa desde hace al menos 4 semanas, confirmada endoscópicamente (pancolonoscopia) e histológicamente. Será necesaria una nueva pancolonoscopia si no se dispone de pruebas documentadas que evidencien que se ha realizado en los 12 meses anteriores. Si está disponible, se requerirá solo una nueva colonoscopia para visualizar la parte afectada del colon con el fin de evaluar el valor inicial de la puntuación del IAE.
    4. Un Índice de Actividad de la Enfermedad comprendido entre 3 y 6, ambos inclusive (colitis ulcerosa leve) con una puntuación de hemorragia rectal de al menos 1.
    5. Aminosalicilatos orales de fondo estables (mesalazina, balsalazida, olsalazina) o tratamientos estándar con sulfasalazina durante 4 semanas o más antes de las evaluaciones de selección.
    6. Si son mujeres, no estar embarazadas ni en período de lactancia.
    7. En el caso de las mujeres en edad fértil (MEF), disposición para evitar el embarazo durante el período de tratamiento y durante al menos 4 semanas después de la última dosis del fármaco.
    Una MEF se define como cualquier mujer que haya experimentado menarquia y que no se haya sometido a una esterilización quirúrgica con éxito (histerectomía, ligadura bilateral de trompas u ovariectomía bilateral) o que no sea postmenopáusica (definida como amenorrea > 12 meses consecutivos).
    Las MEF debe usar un método anticonceptivo eficaz durante todo el ensayo y hasta las primeras menstruaciones tras un período de 30 días posterior a la última dosis de la medicación del ensayo. Deben estar recibiendo una pauta estable, durante al menos 1 mes, de anticonceptivos orales, implante anticonceptivo o inyección depot, parche anticonceptivo, dispositivo intrauterino (DIU), preservativo y agente espermicida, o diafragma y agente espermicida.Se informará a la paciente del resultado de la prueba del embarazo y de cuáles son los anticonceptivos permitidos y cuándo es obligatorio utilizarlos.
    E.4Principal exclusion criteria
    1. Crohn?s disease and indeterminate colitis.
    2. Current or previous (in the last 10 days preceding the screening) use of systemic corticosteroids.
    3. Use of systemic antibiotics in the last 10 days preceding the screening.
    4. Use of systemic NSAIDs on a repeat basis in the last 10 days preceding the screening.
    5. Use of probiotics started within 10 days preceding the screening. A stable regimen from at least 10 days prior to screening is allowed but the patient must be willing to continue up to the end of the study.
    6. Use of immunosuppressants or biological agents within the last 6 weeks preceding the screening.
    7. Stool culture positive for enteric pathogens (eg, Shigella, Salmonella, Yersinia, Campylobacter) or toxins (C.difficile).
    8. Significantly impaired liver, renal, pulmonary or cardiovascular function as assessed by the investigator.
    9. History of colon resection.
    10. Diverticulitis, symptomatic diverticulosis.
    11. Active peptic ulcer disease.
    12. Proctitis (extent of inflammation <15 cm from the anus).
    13. Bleeding disorders
    14. Rectal therapy with any therapeutic enemas or suppositories with the exception of those required for endoscopy during the 10 days preceding the screening.
    15. Active or chronic infection(s) or malignancies.
    16. Known hypersensitivity to the active ingredient and excipients of the study drug.
    17. Simultaneous participation in another clinical trial, or participation in any clinical trial involving investigational drugs within 3 months from enrolment into the present study.
    18. Any physical or psychological condition in a patient that could let the investigator suspect his/her poor compliance.
    19. Patients treated with L-carnitine or its ester derivates during the three months preceding the screening.
    1. Enfermedad de Crohn y colitis indeterminada.
    2. Uso actual o anterior (en los 10 últimos días anteriores a la selección) de corticoesteroides sistémicos.
    3. Uso de antibióticos sistémicos en los 10 últimos días anteriores a la selección.
    4. Uso de FAINE sistémicos repetidamente en los 10 últimos días anteriores a la selección.
    5. Uso de probióticos iniciado en los 10 últimos días anteriores a la selección. Se permite una pauta estable desde al menos 10 días antes de la selección, pero el paciente debe estar dispuesto a continuar hasta el final del estudio.
    6. Uso de inmunosupresores o productos biológicos en las 6 últimas semanas anteriores a la selección.
    7. Cultivo fecal positivo para patógenos entéricos (p. ej.: Shigella, Salmonella, Yersinia, Campylobacter) o toxinas (C.difficile).
    8. Deterioro significativo de la función hepática, renal, pulmonar o cardiovascular, evaluadas por el investigador.
    9. Antecedentes de resección del colon.
    10. Diverticulitis, diverticulosis sintomática.
    11. Enfermedad de úlcera péptica activa.
    12. Proctitis (grado de inflamación < 15 cm desde el ano).
    13. Trastornos hemorrágicos
    14. Terapia rectal con enemas terapéuticos o supositorios, con la excepción de los usados para la endoscopia, en los 10 días anteriores a la selección.
    15. Infecciones o neoplasias malignas activas o crónicas.
    16. Hipersensibilidad conocida al principio activo y a los excipientes del fármaco del estudio.
    17. Participación simultánea en otro ensayo clínico, o participación en cualquier ensayo clínico que incluya fármacos en investigación en los 3 meses anteriores a la inclusión en el presente estudio.
    18. Cualquier enfermedad física o psicológica en un paciente que pueda llevar al investigador a sospechar de un cumplimiento deficiente.
    19. Tratamiento con L-carnitina o ésteres derivados en los 3 meses anteriores a la selección.
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint will be the clinical/endoscopic remission defined as a Disease Activity Index at the end of treatment ? 2 with rectal bleeding sub-score = 0 and no other individual sub-score >1.
    El criterio de valoración principal será la remisión clínica/endoscópica definida como un Índice de Actividad de la Enfermedad al final del tratamiento ? 2 con una puntuación de hemorragia rectal = 0 y ninguna otra puntuación individual > 1.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Disease Activity Index at the end of treatment ? 2 with rectal bleeding sub-score = 0 and no other individual sub-score > 1.
    Índice de Actividad de la Enfermedad al final del tratamiento ? 2 con una puntuación de hemorragia rectal = 0 y ninguna otra puntuación individual > 1.
    E.5.2Secondary end point(s)
    Secondary endpoints will be:
    ? Rectal bleeding evaluation by means of DAI sub-score (from 0 to 3).
    ? Stool frequency evaluation by means of DAI sub-score (from 0 to 3).
    A clinical response for each of these parameters is defined as a sub-score improvement of at least 1 point over baseline.
    The histological response to the treatments, defined as an improvement of the Histological Index (HI ? see Appendix III) of at least 1 point at the end of the study (a final HI score of ?1 will be defined as a histological remission) will also be evaluated as additional exploratory end-point.
    The serum C-reactive protein and Fibrinogen will be monitored to investigate possible correlation between clinical/endoscopic outcome and serum level of these inflammatory markers.
    A validated specific questionnaire, the SIBDQ by McMaster University, will be administered to evaluate changes in patients? Quality of Life.
    The safety and tolerability of the treatments will be investigated through AEs recording, vital signs, ECG and laboratory evaluation.
    Los criterios de valoración secundarios serán:
    ? Evaluación de la hemorragia rectal mediante la puntuación del IAE (de 0 a 3).
    ? Evaluación de la frecuencia de deposiciones mediante la puntuación del IAE (de 0 a 3).
    Una respuesta clínica para cada uno de estos parámetros se define como una mejoría en la puntuación de al menos 1 punto con respecto al valor inicial.
    La respuesta histológica a los tratamientos, definida como una mejoría del índice Histológico (IH - ver Apéndice III) de al menos 1 punto al final del estudio (una puntuación final en el IH de ?1 se definirá como una remisión histológica) también se evaluará como un criterio de valoración exploratorio adicional.

    La proteína C reactiva y el fibrinógeno en suero se controlarán para investigar una posible correlación entre el resultado clínico/endoscópico y el nivel de suero de estos marcadores inflamatorios.

    Se administrará un cuestionario específico validado, el SIBDQ de la McMaster University, para evaluar los cambios en la calidad de vida de los pacientes.
    La seguridad y tolerabilidad de los tratamientos serán investigadas mediante los registros de AA, las constantes vitales, los ECG y la evaluación del laboratorio.
    E.5.2.1Timepoint(s) of evaluation of this end point
    A clinical response for each of these parameters is defined as a sub-score improvement of at least 1 point over baseline.
    The histological response to the treatments, defined as an improvement of the Histological Index (HI ? see Appendix III) of at least 1 point at the end of the study (a final HI score of ?1 will be defined as a histological remission) will also be evaluated as additional exploratory end-point.
    The serum C-reactive protein and Fibrinogen will be monitored to investigate possible correlation between clinical/endoscopic outcome and serum level of these inflammatory markers.
    A validated specific questionnaire, the SIBDQ by McMaster University, will be administered to evaluate changes in patients?
    La respuesta histológica a los tratamientos, definida como una mejoría del índice Histológico (IH - ver Apéndice III) de al menos 1 punto al final del estudio (una puntuación final en el IH de ?1 se definirá como una remisión histológica) también se evaluará como un criterio de valoración exploratorio adicional.
    La proteína C reactiva y el fibrinógeno en suero se controlarán para investigar una posible correlación entre el resultado clínico/endoscópico y el nivel de suero de estos marcadores inflamatorios.
    Se administrará un cuestionario específico validado, el SIBDQ de la McMaster University, para evaluar los cambios en la calidad de vida de los pacientes.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned7
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA60
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Austria
    France
    Germany
    Hungary
    Latvia
    Lithuania
    Poland
    Spain
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of the trial will be when the last patient enrolled complete the study proceds for last visit.
    A patient (even last ptient enrolled) can finalize the study participation when:
    a.development of any adverse event by reason of which continuation in the trial is considered inappropriate;
    b.patient?s request to discontinue for any reason;
    c.needing to start a not allowed concomitant therapy;
    d.pregnancy.
    El final del estudio se considerará cuando el último paciente incluido complete los procedimientos para la última visita.
    Un paciente (hasta el último paciente incluido) puede finalizar su participación en el estudio por:
    a.desarrollo de cualquier acontecimiento adverso por el cual la continuación en el ensayo se considere inadecuada;
    b.petición del sujeto de retirarse por cualquier motivo;
    c.necesidad de empezar un tratamiento concomitante no permitido;
    d.embarazo.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days10
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months2
    E.8.9.2In all countries concerned by the trial days10
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 444
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 0
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state50
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 444
    F.4.2.2In the whole clinical trial 444
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    NA
    NA
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2012-02-28
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2012-02-07
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2013-08-13
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA